A Comprehensive Monograph on Serine (DB00133): From Core Metabolism to Therapeutic Frontiers

Executive Summary

Serine is a proteinogenic α-amino acid that occupies a position of profound significance in human biochemistry and pharmacology. Traditionally classified as a nutritionally non-essential amino acid due to the body's capacity for endogenous synthesis, a more nuanced understanding now recognizes it as "conditionally essential." This revised status reflects the reality that endogenous production is often insufficient to meet the metabolic demands imposed by various physiological states, such as rapid growth and development, or pathological conditions, including certain genetic and neurodegenerative disorders. With the DrugBank identifier DB00133 and CAS Number 56-45-1, this small molecule is far more than a simple structural component; it is a central hub of intermediary metabolism.

The metabolic indispensability of L-serine, the naturally occurring stereoisomer, stems primarily from its role as the principal donor of one-carbon units to the folate cycle. This function establishes a direct and critical biochemical link between central carbon metabolism (glycolysis) and the de novo synthesis of essential biomolecules, including purines and pyrimidines, the building blocks of DNA and RNA. Consequently, serine metabolism is intrinsically tied to cellular proliferation, growth, and repair. Furthermore, L-serine serves as a key precursor for the synthesis of other amino acids, such as glycine and cysteine, and is a foundational component of critical lipids, including phospholipids and sphingolipids, which are vital for the structural integrity and function of all cell membranes, particularly within the central nervous system (CNS).

A remarkable feature of serine biochemistry is the functional dichotomy between its stereoisomers. While L-serine participates in the broad metabolic functions described above and acts as an inhibitory neurotransmitter agonist, its enantiomer, D-serine, serves a distinct and vital role as a potent neuromodulator in the CNS. Synthesized from L-serine in glial cells and neurons, D-serine is a primary co-agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor, a key mediator of excitatory neurotransmission. By facilitating NMDA receptor activation, D-serine plays a crucial part in synaptic plasticity, long-term potentiation, and the cellular mechanisms underlying learning and memory.

This multifaceted biological profile has given rise to a diverse and expanding range of therapeutic and commercial applications. Serine is a standard component in total parenteral nutrition formulations and is widely utilized in the cosmetics industry as a natural moisturizing agent. Clinically, it is emerging as a therapeutic agent for a spectrum of complex disorders. High-dose L-serine supplementation has shown efficacy in genetic conditions such as hereditary sensory and autonomic neuropathy type 1 (HSAN1) and is under active investigation in Phase II clinical trials for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Concurrently, the metabolic dependency of many cancer cells on serine has positioned the serine synthesis pathway as a promising target for novel anti-cancer therapies based on inhibition and depletion. The molecule's safety profile is generally favorable, though a nuanced understanding of its pharmacokinetics and the distinct toxicology of its D-isomer is essential for its continued therapeutic development. This report provides an exhaustive analysis of serine, synthesizing current knowledge of its physicochemical properties, complex metabolic roles, comprehensive pharmacology, clinical applications, and safety profile.

Identification and Physicochemical Characteristics

The unambiguous identification and characterization of a molecule's physical and chemical properties are foundational to understanding its biological activity and developing its applications in research, medicine, and industry. This section provides a comprehensive summary of the nomenclature, structural attributes, and analytical profile for serine.

Nomenclature and Identifiers

To ensure precise identification across scientific literature and regulatory databases, serine is cataloged under multiple names and unique identifiers. The historical context of its discovery, first isolated from silk protein (sericum in Latin) in 1865 by Emil Cramer, has contributed to its array of synonyms, which predate modern systematic nomenclature.[1]

• Generic Name: Serine [3]
• Systematic IUPAC Name: 2-Amino-3-hydroxypropanoic acid [1]
• Synonyms: A comprehensive list of synonyms includes L-Serine, (S)-Serine, (S)-2-Amino-3-hydroxypropanoic acid, alpha-Amino-beta-hydroxypropionic acid, β-Hydroxyalanine, H-Ser-OH, L-2-Amino-3-hydroxypropionic Acid, Ser, Serina, and Serinum.[1]
• Database Identifiers: Key identifiers used in major chemical and pharmacological databases are listed in Table 1.

Molecular Structure and Properties

Serine's chemical structure dictates its physicochemical properties, which in turn govern its biological functions, from protein folding to enzymatic catalysis. It is an α-amino acid, meaning its core structure consists of a central carbon atom (the α-carbon) covalently bonded to an α-amino group (−NH2​), a carboxyl group (−COOH), a hydrogen atom, and a unique side chain.[1]

The defining feature of serine is its side chain, which is a hydroxymethyl group (−CH2​OH). This group imparts several critical properties. First, the hydroxyl group is polar and capable of forming hydrogen bonds, making serine a hydrophilic amino acid. This characteristic is crucial for its role in protein structure, where it often resides on the surface of proteins, interacting with the aqueous cellular environment, and participating in the hydrogen-bond networks that stabilize protein conformations.[2] Second, the hydroxyl group is a reactive site for post-translational modifications, most notably phosphorylation and O-linked glycosylation, which are fundamental mechanisms for regulating protein function and cell signaling.[2]

At physiological pH (approximately 7.4), the amino group is protonated (−NH3+​) and the carboxyl group is deprotonated (−COO−), causing the molecule to exist as a zwitterion with a net neutral charge.[1] Its physical form is a white to almost-white crystalline powder. Key molecular and physical properties are summarized in Table 1.

Table 1: Chemical and Physical Properties of Serine (DB00133)

Property	Value	Source(s)
IUPAC Name	(2S)-2-amino-3-hydroxypropanoic acid	1
CAS Number	56-45-1	3
DrugBank ID	DB00133	1
PubChem ID	5951	5
ChEBI ID	CHEBI:17115	1
Molecular Formula	C3​H7​NO3​	3
Average Weight	105.0926 g/mol	3
Monoisotopic Weight	105.042593095 Da	3
Physical State	Solid (white to almost-white powder/crystal)	7
Melting Point	228 °C (decomposes)	7
Water Solubility	Soluble (up to 100 mM)	7
Other Solubilities	Soluble in DMSO	6
Specific Rotation [α]20/D	+14.3 to +15.5 deg (C=10, HCl(1+5))	7

Spectroscopic and Analytical Profile

Definitive identification and quantification of serine in biological matrices and pharmaceutical preparations rely on modern analytical techniques. The available data provide a spectroscopic fingerprint for the molecule.

• Mass Spectrometry (MS): Mass spectrometry is a cornerstone for metabolomics and quantitative analysis. Tandem mass spectrometry (MS/MS) data for serine has been acquired using instruments such as a Quattro Triple Quadrupole (QQQ) mass spectrometer, typically in positive ionization mode. This technique provides structural information through fragmentation patterns and allows for highly sensitive and specific quantification.[15] Additionally, Gas Chromatography-Mass Spectrometry (GC-MS) spectra, using methods like Electron Ionization (EI-B), are available and are frequently used for analyzing derivatized amino acids in complex mixtures.[16]
• Nuclear Magnetic Resonance (NMR) Spectroscopy: Proton NMR (1H NMR) spectroscopy provides detailed information about the chemical structure and environment of hydrogen atoms within the molecule. Spectra for serine are typically recorded in an aqueous solvent like water (H2​O) at a physiological pH of 7.0, using a high-field instrument (e.g., 500 MHz). This analysis confirms the presence and connectivity of protons in the molecule, serving as a definitive method for structural verification.[17]

Biochemistry and Endogenous Metabolism

Serine is far more than a simple building block for proteins; it is a central nexus in intermediary metabolism, linking major pathways of energy production, nucleotide synthesis, and lipid biosynthesis. While the human body can synthesize serine, its classification as a non-essential amino acid is increasingly viewed as an oversimplification. The severe pathologies arising from genetic defects in its synthesis and the high metabolic demand in certain physiological and disease states underscore its indispensable nature, leading to its reclassification as a "conditionally essential" amino acid.

Biosynthesis Pathways

The body maintains its serine pool through two primary biosynthetic routes, which are tightly regulated and exhibit tissue-specific activity.

De Novo Synthesis from Glycolysis

The main pathway for de novo L-serine synthesis branches directly from glycolysis, a fundamental process of glucose metabolism. This three-step enzymatic pathway converts the glycolytic intermediate 3-phosphoglycerate (3-PG) into L-serine.[1] This origin from glycolysis establishes a direct link between the cell's central carbon and energy metabolism and the production of a critical anabolic precursor. The pathway proceeds as follows:

1. Oxidation: The first committed step is the oxidation of 3-PG to 3-phosphohydroxypyruvate, a reaction catalyzed by the NAD⁺-dependent enzyme phosphoglycerate dehydrogenase (PGDH).[6]
2. Transamination: The resulting α-keto acid, 3-phosphohydroxypyruvate, undergoes transamination. The amino group is typically donated by glutamate, which is converted to α-ketoglutarate. This reaction is catalyzed by phosphoserine aminotransferase (PSAT) and yields 3-phosphoserine.[1]
3. Hydrolysis: The final step is the irreversible hydrolysis of the phosphate group from 3-phosphoserine to produce L-serine. This reaction is catalyzed by phosphoserine phosphatase (PSP). This final step is considered the rate-limiting step of the pathway and is subject to allosteric feedback inhibition by the end product, L-serine, allowing the cell to regulate its synthesis according to metabolic demand.[6]

Interconversion with Glycine

A second major route for serine synthesis is its reversible interconversion with glycine. This reaction is catalyzed by the pyridoxal phosphate-dependent enzyme serine hydroxymethyltransferase (SHMT). In this reaction, a one-carbon unit (in the form of a hydroxymethyl group) is transferred from serine to the cofactor tetrahydrofolate (THF), producing glycine and 5,10-methylene-THF. The reversibility of this reaction means that it can also proceed in the opposite direction, synthesizing serine by transferring a one-carbon unit from 5,10-methylene-THF to glycine.[1] The direction of the net flux through this reaction is determined by the relative concentrations of the substrates and the metabolic needs of the cell. In healthy humans, this pathway accounts for a significant portion of the whole-body glycine flux.[20]

Tissue-Specific Synthesis

Serine biosynthesis is not uniformly active across all tissues. The kidneys are a major site of de novo synthesis and are considered the primary source of serine released into the systemic circulation, particularly during fasting states.[19] Within the central nervous system, which has limited capacity to transport serine across the blood-brain barrier, local synthesis is critical. Astrocytes, a type of glial cell, are the primary sites of serine synthesis in the brain, providing this essential amino acid to neurons.[20]

Serine as a Central Metabolic Hub

The metabolic significance of serine extends far beyond its role in protein synthesis. It serves as a critical precursor for a diverse array of essential biomolecules and is the primary source of one-carbon units, placing it at the crossroads of several major metabolic networks.

One-Carbon Metabolism

Perhaps the most crucial metabolic role of L-serine is as the major endogenous donor of one-carbon units.[19] The catabolism of serine to glycine by SHMT is the principal reaction that feeds one-carbon units into the folate cycle by generating 5,10-methylene-THF.[3] This folate-bound one-carbon unit can then be interconverted into other oxidation states (e.g., 5,10-methenyl-THF, 10-formyl-THF, 5-methyl-THF) and utilized in a wide range of biosynthetic reactions. Studies using stable isotopic tracers in humans have demonstrated that virtually all methyl groups used for the total body remethylation of homocysteine to methionine are ultimately derived from serine.[19] This positions serine metabolism as a critical regulator of the methylation potential of all cells, which has profound implications for epigenetics (DNA and histone methylation) and the synthesis of molecules like creatine and phosphatidylcholine.

Precursor for Biomolecule Synthesis

The carbon and nitrogen atoms of serine are incorporated into a vast and vital array of biomolecules:

• Proteins: As one of the 20 common proteinogenic amino acids, the L-stereoisomer of serine is a fundamental constituent of proteins, encoded by six different codons (UCU, UCC, UCA, UCG, AGU, and AGC).[1]
• Amino Acids: Serine is the direct metabolic precursor for both glycine (via the SHMT reaction) and cysteine. The synthesis of cysteine from serine occurs via the transsulfuration pathway, where serine condenses with homocysteine to form cystathionine, which is then cleaved to yield cysteine.[1]
• Nucleotides: The one-carbon units derived from serine are indispensable for the de novo synthesis of nucleotides. They are required for the formation of the purine ring (in adenine and guanine) and for the methylation of deoxyuridine monophosphate (dUMP) to form deoxythymidine monophosphate (dTMP), a pyrimidine base unique to DNA. This function mechanistically links serine metabolism directly to the synthesis of genetic material and is a primary reason for the high serine requirement of rapidly dividing cells.[1]
• Lipids: Serine provides the backbone for the synthesis of sphingolipids, a class of lipids essential for cell membrane structure and signaling. The first step in sphingolipid synthesis is the condensation of serine with palmitoyl-CoA to form 3-ketosphinganine.[1] Serine is also a key component of the phospholipid phosphatidylserine, which is particularly abundant in the inner leaflet of the plasma membrane of brain cells and plays critical roles in cell signaling and apoptosis.[10]

The "Conditionally Essential" Status

While serine is classified as a non-essential amino acid because it can be synthesized by the body, this classification is increasingly considered conditional.[1] This means that under certain conditions, endogenous synthesis is insufficient to meet physiological demands, making a dietary source essential. The evidence for this status is compelling and multifaceted.

First, the existence of severe genetic disorders caused by defects in the serine biosynthesis pathway provides definitive proof. Conditions such as 3-phosphoglycerate dehydrogenase (PGDH) deficiency result in catastrophic neurological symptoms, including congenital microcephaly and intractable seizures, because the brain's high demand for serine cannot be met by dietary intake or transport across the blood-brain barrier alone.[1] The therapeutic response to exogenous serine supplementation in these patients underscores the essentiality of an adequate serine supply for normal neurological development.

Second, rapidly proliferating cells, such as activated immune cells and many types of cancer cells, exhibit an exceptionally high demand for serine. This demand is driven by the need for one-carbon units for nucleotide synthesis and for the production of proteins and lipids required to build new cells. In these contexts, both the uptake of extracellular serine and the upregulation of the de novo synthesis pathway are often critical for sustaining rapid growth, highlighting a state of heightened metabolic dependency.[19] This metabolic reprogramming in cancer has made the serine synthesis pathway a prominent target for therapeutic intervention. The inability of normal dietary intake to satisfy this amplified demand in pathological states further supports the concept of conditional essentiality.

Comprehensive Pharmacology

The pharmacology of serine is complex, reflecting its dual identity as a fundamental metabolite and a signaling molecule. Its actions are highly dependent on its stereochemistry, with L-serine and D-serine exhibiting distinct and sometimes opposing physiological effects, particularly within the central nervous system. A thorough understanding of its mechanism of action, pharmacodynamics, and pharmacokinetics is essential for its rational use as a nutritional supplement and therapeutic agent.

Mechanism of Action and Pharmacodynamics

The pharmacodynamic effects of serine are mediated through several distinct mechanisms, ranging from direct receptor interaction to its role as a substrate in critical enzymatic and metabolic pathways.

L-Serine

The actions of L-serine are primarily tied to its central role in metabolism and its function as a neurotransmitter.

• Metabolic and Proliferative Effects: The fundamental mechanism of L-serine is its participation as a substrate in a multitude of biosynthetic pathways. It is essential for the synthesis of proteins, enzymes, and muscle tissue.[3] Its most critical pharmacodynamic effect in this context is its role in one-carbon metabolism. The enzymatic conversion of L-serine to glycine by serine hydroxymethyltransferase generates 5,10-methylene-tetrahydrofolate. This molecule is the primary donor of one-carbon units for the synthesis of purine and pyrimidine nucleotides, which are the essential components of DNA and RNA. By fueling nucleotide synthesis, L-serine directly supports cell growth, proliferation, and tissue development.[3] Additionally, it is required for the proper metabolism of fats and fatty acids and contributes to immune function through the production of antibodies.[3]
• Neurotransmission: Beyond its metabolic roles, L-serine also functions as a direct signaling molecule in the CNS. It acts as an agonist at inhibitory glycine receptors (GlyRs).[5] Activation of these ligand-gated chloride channels leads to hyperpolarization of the postsynaptic neuron, reducing its excitability. This inhibitory action confers a neuroprotective effect, particularly under conditions of excessive excitatory stimulation, such as glutamate-induced neurotoxicity following ischemia or trauma.[11]

D-Serine

In contrast to its L-enantiomer, D-serine is not a protein building block but a specialized signaling molecule, or "gliotransmitter," in the brain.

• Neuromodulation and NMDA Receptor Activation: D-serine is synthesized endogenously from L-serine by the enzyme serine racemase, which is found in both astrocytes and neurons.[1] Its primary and most significant pharmacodynamic effect is to act as a potent co-agonist at the glycine-binding site (also known as the NR1 or GluN1 subunit) of the N-methyl-D-aspartate (NMDA) receptor.[1] The NMDA receptor is a unique glutamate receptor that requires the simultaneous binding of two different agonists for its activation: glutamate must bind to the GluN2 subunit, and a co-agonist—either D-serine or glycine—must bind to the GluN1 subunit. D-serine is considered the primary endogenous co-agonist at synaptic NMDA receptors and is often more potent than glycine in this role.[1] By enabling the opening of the NMDA receptor ion channel in response to glutamate, D-serine is a critical facilitator of excitatory neurotransmission and is essential for inducing long-term potentiation (LTP), a persistent strengthening of synapses that is a key cellular mechanism underlying learning and memory.[10]

This metabolic relationship creates a sophisticated and finely tuned regulatory system in the brain. The body uses an inhibitory signaling molecule (L-serine, an agonist at inhibitory GlyRs) as the direct precursor for a molecule that potentiates the primary excitatory neurotransmitter system (D-serine, a co-agonist at excitatory NMDA receptors). The enzyme serine racemase thus functions as a critical control point, capable of switching the functional output of serine metabolism from inhibitory to excitatory potentiation. The regulation of this enzyme's activity is therefore paramount for maintaining the brain's excitatory/inhibitory balance, and its dysregulation has been implicated in the pathophysiology of disorders like schizophrenia.[34]

Enzymatic and Broader Signaling Roles

• Serine Proteases: The serine molecule itself is integral to the catalytic function of a large and vital class of enzymes known as serine proteases. In the active site of these enzymes (which include digestive enzymes like trypsin and chymotrypsin, as well as key proteins in the blood coagulation cascade), a specific serine residue acts as the nucleophile that attacks the peptide bond of the substrate, initiating catalysis.[2]
• Protein Phosphorylation: The hydroxyl (−OH) group on serine's side chain is a major target for reversible phosphorylation by enzymes called protein kinases. The addition of a bulky, negatively charged phosphate group to a serine residue (forming phosphoserine) can dramatically alter a protein's conformation, activity, localization, or interaction with other proteins. This process is a fundamental mechanism of signal transduction in virtually all cellular processes.[2]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of serine is characterized by rapid absorption and clearance, which has significant implications for its use as an oral therapeutic agent. While endogenous serine metabolism is complex and tissue-specific, the disposition of exogenously administered L-serine has been characterized in human studies.

Table 2: Summary of L-Serine Pharmacokinetic Parameters in Humans

Pharmacokinetic Parameter	Reported Value	Study Population/Context	Source(s)
Time to Peak Concentration (Tmax​)	0.75–2 hours	Healthy subjects (oral syrup)	37
Elimination Half-life (t1/2​)	1.48 hours	Single patient (oral supplementation)	38
	1.45 hours	Model-derived from 10 healthy individuals	39
	7–14 hours	Healthy subjects (oral syrup, multiple dose)	37
	~3.2 hours	Non-psychotic controls	40
Apparent Volume of Distribution (Vd​)	21.6 L	Single patient (oral supplementation)	38
	~140 L	Model-derived from human data
Clearance (CL)	10.1 L/h	Single patient (oral supplementation)	38
Oral Bioavailability (F)	~60%	Estimated based on animal extraction data	38

Absorption

Following oral administration, L-serine is absorbed rapidly from the gastrointestinal tract, leading to a swift increase in plasma concentrations.[38] However, it is subject to substantial first-pass metabolism by the liver. After absorption into the portal circulation, a significant fraction is extracted by hepatocytes before reaching systemic circulation. Studies in animal models have reported first-pass hepatic extraction rates as high as 40-58%.[21] Based on these preclinical data, the oral bioavailability of L-serine in humans is estimated to be approximately 60%.[38]

Distribution

Pharmacokinetic modeling suggests that serine distributes into a large apparent volume, with estimates in humans ranging from approximately 21.6 L to 140 L.[38] A larger volume of distribution indicates that the compound does not remain confined to the plasma but distributes into tissues. Serine is transported across cellular membranes by specific amino acid transport systems, including the sodium-dependent Systems A and ASC.[20] Transport into the central nervous system across the blood-brain barrier is known to be inefficient, which is why the brain relies heavily on its own de novo synthesis of serine.[42] This pharmacokinetic barrier presents a significant challenge for therapeutic strategies that rely on oral L-serine supplementation to address neurological conditions rooted in CNS-specific serine deficiency. Even if high systemic concentrations are achieved, they may not translate to therapeutically relevant concentrations within the brain, suggesting that more advanced strategies targeting CNS transport or synthesis may be required for optimal efficacy.

Metabolism

Exogenously administered serine enters the body's complex metabolic network. It is taken up and utilized by various tissues, with the liver and skeletal muscle being major sites of extraction from the circulation.[21] It can be converted to pyruvate and enter gluconeogenesis, catabolized to glycine, or used as a precursor for the synthesis of cysteine, lipids, and other molecules.[20] Endogenous serine homeostasis is maintained by a balance between de novo synthesis (primarily in the kidneys and brain), release from protein turnover, and tissue uptake.[19] The enantiomer, D-serine, is metabolized via a distinct pathway, primarily through oxidative deamination by the enzyme D-amino acid oxidase (DAAO), which is highly expressed in the kidneys and certain brain regions.[11]

Elimination and Half-life

L-serine is cleared from the plasma very rapidly. Multiple human pharmacokinetic studies have consistently reported a short elimination half-life, typically around 1.5 hours.[38] Some studies have reported longer half-lives, which may reflect differences in study design (e.g., multiple dosing) or patient populations with altered metabolism.[37] Due to this rapid clearance, approximately 97% of an administered dose is eliminated from circulation within about 7.4 hours (five half-lives). This pharmacokinetic profile necessitates frequent, divided dosing regimens—typically at least three times per day—to maintain elevated and stable plasma concentrations when L-serine is used as a therapeutic supplement.[38] D-serine is primarily cleared by the kidneys, with significantly less tubular reabsorption than L-serine, leading to its excretion in urine.[11]

Clinical and Therapeutic Applications

The central role of serine in human metabolism and neurobiology has led to its application in a diverse range of fields, from fundamental nutritional support to cutting-edge therapeutics for complex diseases. Its uses span established roles in parenteral nutrition and consumer cosmetics to investigational therapies targeting neurodegeneration, genetic disorders, and cancer.

Established Clinical and Nutraceutical Uses

Serine's most well-established applications are in providing basic nutritional and physiological support.

• Parenteral Nutrition: L-serine is a standard and essential component of numerous total parenteral nutrition (TPN) solutions, including brands such as Aminosyn II 7%, Clinimix, Clinisol 15, Travasol 10, and Trophamine 10%.[3] These intravenous formulations are critical for providing amino acid nutrition to patients who cannot absorb nutrients through the gastrointestinal tract, such as those with proven insufficient enteral resorption.[46] Its inclusion has been validated in completed Phase 3 clinical trials for specific patient populations, including low birth weight infants who have high anabolic demands for growth and development.[47]
• Dietary and Medical Food Supplementation: As a dietary supplement, L-serine is used for general amino acid supplementation.[3] More specifically, it is formulated as a "Food for Special Medical Purposes" for the dietary management of rare inborn errors of serine biosynthesis. In conditions such as 3-phosphoglycerate dehydrogenase (PGDH) deficiency or phosphoserine phosphatase deficiency, endogenous serine production is impaired, leading to severe neurological deficits. Oral L-serine supplementation is a primary treatment for these disorders.[1]
• Cosmetic and Dermatological Applications: L-serine is widely incorporated into skin and hair care products due to its properties as a natural moisturizing factor (NMF).[3] As a hydrophilic amino acid, it functions as a humectant and conditioning agent, helping to attract and retain moisture in the skin and hair. This action supports skin hydration, elasticity, and firmness, and can improve the texture and strength of hair.[9] It is a key biomarker for skin health, as its levels in the stratum corneum are correlated with skin barrier function and hydration.[54]

Investigational and Emerging Therapeutic Areas

The expanding understanding of serine's role in pathophysiology has opened up numerous avenues for its investigation as a therapeutic agent, as summarized in Table 3. A notable feature of this research landscape is a striking therapeutic dichotomy: for one class of diseases (e.g., genetic deficiencies, certain neuropathies), the strategy is high-dose supplementation to correct a deficit, while for another major disease class (cancer), the strategy is metabolic inhibition or depletion to starve proliferating cells. This highlights that any therapeutic intervention must be highly tailored to the specific metabolic context of the disease.

Neurodegenerative and Psychiatric Disorders

• Amyotrophic Lateral Sclerosis (ALS): L-serine is being investigated as a potential neuroprotective agent in ALS. The rationale is partly based on the hypothesis that it can competitively inhibit the misincorporation of the environmental neurotoxin β-N-methylamino-L-alanine (BMAA) into proteins.[55] An FDA-approved Phase I clinical trial (NCT01835782) in 20 ALS patients established that oral L-serine at doses up to 15 g twice daily is safe and well-tolerated. Exploratory efficacy data from this trial suggested a possible dose-related slowing of disease progression as measured by the ALSFRS-R score.[1] These promising results led to the initiation of a Phase IIa study (NCT03580616) to further evaluate its tolerability and efficacy.[57]
• Alzheimer's Disease (AD): The role of serine metabolism in AD is complex and under active investigation. Dysregulation of both L-serine synthesis in astrocytes and D-serine levels has been implicated in AD pathophysiology.[6] D-serine has been proposed as a potential cerebrospinal fluid biomarker for early diagnosis.[1] A Phase II clinical trial (NCT03062449) is currently testing the effects of L-serine supplementation in patients with early-stage AD or mild cognitive impairment.[59]
• Schizophrenia: A leading hypothesis for the negative and cognitive symptoms of schizophrenia involves hypofunction of the NMDA receptor. Because D-serine is a crucial co-agonist for this receptor, it is being studied as an adjunctive therapy to enhance NMDA signaling. Clinical studies have explored the use of D-serine to ameliorate these difficult-to-treat symptoms.[1]
• GRIN-related Encephalopathy: These are severe neurodevelopmental disorders caused by mutations in the genes (e.g., GRIN1, GRIN2A, GRIN2B) that encode NMDA receptor subunits. For patients with loss-of-function variants, L-serine acts as an agonist to boost receptor activity. A recent Phase 2A non-randomized study involving 24 children with these variants found that L-serine treatment (500 mg/kg/day for one year) was safe and well-tolerated.[61]

Metabolic and Genetic Disorders

• Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1): This neuropathy is caused by mutations in the SPTLC1 gene, which leads the serine palmitoyltransferase enzyme to mistakenly use alanine or glycine instead of serine, resulting in the production of neurotoxic 1-deoxysphingolipids.[20] A landmark randomized, placebo-controlled trial (NCT01733407) provided Class I evidence that high-dose oral L-serine supplementation (400 mg/kg/day) is an effective therapy. The treatment was safe, significantly reduced the levels of the neurotoxic biomarkers, and slowed the clinical progression of the disease.[38]
• Diabetes Mellitus: Altered serine metabolism has been linked to diabetes and its complications. Preclinical and observational studies suggest L-serine may play a role in improving glucose control and insulin sensitivity, and could potentially prevent diabetic neuropathy, making it an area of active research.[6]

Oncology

In stark contrast to its use as a supplement, the metabolic pathways of serine are a major target for inhibition in cancer therapy. Many cancer cells are highly dependent on the serine synthesis pathway to fuel their rapid proliferation, providing building blocks for nucleotides, proteins, and lipids, as well as contributing to redox balance.[19] This metabolic addiction represents a therapeutic vulnerability. Research is focused on two main strategies: 1) developing small-molecule inhibitors of key enzymes in the pathway, particularly PHGDH, and 2) dietary restriction of serine and glycine to starve tumors of this critical nutrient.[66]

Table 3: Overview of Clinical Trials and Investigational Uses of Serine

Condition/Disease	Serine Isomer	Trial Phase / ID	Dosage Regimen	Key Findings/Status	Source(s)
Amyotrophic Lateral Sclerosis (ALS)	L-Serine	Phase I / NCT01835782	0.5 g to 15 g twice daily	Safe and well-tolerated; suggested possible dose-related slowing of progression.	1
	L-Serine	Phase IIa / NCT03580616	Not specified	To assess tolerability and preliminary efficacy; status not recruiting as of May 2023.	57
Alzheimer's Disease (AD)	L-Serine	Phase II / NCT03062449	15 g twice daily	Ongoing trial testing effects in early-stage AD.	60
Hereditary Sensory Neuropathy Type 1 (HSAN1)	L-Serine	Randomized Controlled Trial / NCT01733407	400 mg/kg/day	Safe; significantly slowed disease progression and reduced neurotoxic biomarkers (Class I evidence).	38
GRIN-related Encephalopathy	L-Serine	Phase 2A, non-randomized	500 mg/kg/day	Safe and well-tolerated in children with GRIN loss-of-function variants.	61
Parenteral Nutrition (Low Birth Weight)	L-Serine (in combination)	Phase 3 (Completed)	Not specified	Used as a component of TPN for low birth weight infants.	47
Parenteral Nutrition (Insufficient Enteral Resorption)	L-Serine (in combination)	Phase 3 (Completed)	Not specified	Used as a component of TPN for patients with malabsorption.	46

Industrial and Biotechnological Production

The growing demand for L-serine, estimated at 10,000 tons per year for use in pharmaceuticals, food, and cosmetics, has driven the development of various large-scale production methods.[9]

• Traditional Methods: Historically, L-serine was produced by protein hydrolysis, typically from acid hydrolysis of serine-rich sources like silk fibroin.[1] Chemical synthesis routes, for example from methyl acrylate, can produce racemic serine but require subsequent resolution steps, adding complexity and cost.[1]
• Biotechnological Methods: Modern production increasingly relies on biotechnology. Enzymatic catalysis uses isolated enzymes like serine hydroxymethyltransferase to convert precursors like glycine and methanol into L-serine, offering high specificity and purity.[1] Microbial fermentation is emerging as a highly promising and sustainable method. This approach uses metabolically engineered strains of microorganisms, such as Escherichia coli and Corynebacterium glutamicum, to produce high titers of L-serine directly from inexpensive, renewable feedstocks like glucose or glycerol.[71]

Safety, Toxicology, and Interactions

A comprehensive evaluation of the safety profile of serine is critical for its application as a nutritional supplement, cosmetic ingredient, and therapeutic agent. The available data indicate that L-serine is generally safe and well-tolerated, while the primary toxicological concern, nephrotoxicity, is associated with high doses of the D-isomer and appears to be a species-specific phenomenon not observed in humans at therapeutic doses.

General Safety Profile and Adverse Effects

• L-Serine: L-serine is generally regarded as safe (GRAS) by the U.S. Food and Drug Administration for use in food and supplements.[63] Clinical trials have confirmed its favorable safety profile, even at the high doses used in neurodegenerative disease research. In a Phase I trial for ALS, oral doses up to 15 g twice daily were administered, and the treatment was found to be generally well-tolerated.[55] The most frequently reported adverse effects are mild to moderate gastrointestinal issues, such as bloating, nausea, and loss of appetite, particularly at higher doses.[55] Some data suggest that very high doses (>400 mg/kg/day) may lead to reversible neurological effects like nausea, vomiting, nystagmus, and seizures, although these are not commonly observed in clinical trials.[79]
• D-Serine: In human clinical trials, D-serine has also been shown to be well-tolerated, with few side effects occurring at a rate significantly different from placebo.[80] In a large study of schizophrenia patients, the most common adverse events were mouth sores (more prevalent in the D-serine group) and dizziness/headache (more common in the placebo group).[80] One small study noted a higher incidence of proteinuria (protein in the urine) in the D-serine group compared to placebo.[80]
• General Concerns with Amino Acid Supplementation: It is important to note that high-dose supplementation with any single amino acid carries general risks. It can lead to a negative nitrogen balance by creating an imbalance in the amino acid pool, which can impair metabolic efficiency and increase the metabolic load on the kidneys. In children, such supplementation may also pose a risk of growth problems.[48]

Specific Toxicological Concerns

D-Serine Nephrotoxicity

The most significant toxicological finding related to serine is the induction of kidney damage by its D-isomer. However, this phenomenon provides a classic example of the challenges of interspecies extrapolation in toxicology, as the risk appears confined to a specific preclinical model.

• Observations in Rats: High doses of D-serine (>500 mg/kg) consistently and rapidly induce a dose-dependent, reversible acute tubular necrosis in rats.[44] Pathological changes, including necrosis of the straight segment of the proximal tubule, appear within hours of administration. This is accompanied by functional changes such as glucosuria, proteinuria, and aminoaciduria.[45]
• Species Specificity: Crucially, this nephrotoxic effect has not been observed in any other species tested, including mice, rabbits, guinea pigs, dogs, and, most importantly, humans.[44] Across all published human clinical trials, only a single case of abnormal renal values (2+ proteinuria that resolved upon discontinuation) has been reported in relation to D-serine treatment.
• Mechanistic Basis: The unique susceptibility of rats is attributed to physiological differences in renal handling and metabolism of D-serine. Rat kidneys exhibit higher reabsorption of D-serine from the glomerular filtrate and may have differences in the function of D-amino acid oxidase (DAAO), the enzyme that degrades D-serine. This combination leads to high intracellular concentrations in the proximal tubule cells, where oxidative stress generated by DAAO-mediated metabolism is thought to cause cellular damage. Furthermore, the plasma concentrations achieved with therapeutic doses in humans (Cmax ~500 nmol/mL at 120 mg/kg) are well below the toxic threshold identified in rats (Cmax >2,000 nmol/mL).[44] Therefore, while D-serine nephrotoxicity is a well-established preclinical hazard in the rat model, it does not appear to represent a significant clinical risk to humans at currently investigated therapeutic doses.

Excitotoxicity

A theoretical toxicological concern arises from the pharmacodynamic action of D-serine. As a potent co-agonist of the NMDA receptor, D-serine enhances excitatory glutamatergic neurotransmission. Overactivation of this system can lead to excitotoxicity, a process of neuronal damage and death caused by excessive intracellular calcium influx, which is implicated in the pathophysiology of neurodegenerative diseases like Alzheimer's disease and ALS.[80] This raises the possibility that D-serine supplementation could be detrimental in conditions characterized by excessive glutamate signaling.[80] In contrast, L-serine has demonstrated neuroprotective properties, in part through its agonist activity at inhibitory glycine receptors, which can counteract glutamate-mediated excitotoxicity.[11]

Contraindications and Interactions

• Contraindications: Due to a lack of sufficient safety data, L-serine and D-serine supplementation is generally not recommended for individuals who are pregnant or breastfeeding.[48]
• Drug Interactions:
• Specific drug interaction data for L-serine is limited.[3]
• Given its mechanism of action, D-serine is expected to interact with other drugs that modulate the NMDA receptor. It may potentiate the effects of NMDA agonists and antagonize the effects of NMDA receptor inhibitors such as memantine, ketamine, and dextromethorphan.[80]
• Phosphatidylserine, a key metabolite of serine, may have mild blood-thinning effects and could potentially interact with anticoagulant medications (e.g., warfarin) and anti-inflammatory drugs. It may also interfere with anticholinergic drugs and medications used for glaucoma or Alzheimer's disease by increasing acetylcholine levels.[87]
• Food Interactions: There are no known adverse interactions between serine supplements and specific foods. Serine is a natural and ubiquitous component of dietary proteins, found in foods such as meat, dairy, eggs, soy products, and nuts.[2] Dietary composition can influence endogenous serine metabolism; for example, a protein-restricted diet has been shown to upregulate the de novo synthesis of serine in the liver.[11]

Conclusion and Future Directions

Serine (DB00133) is a molecule of profound biological complexity whose importance extends far beyond its traditional classification as a non-essential amino acid. The evidence synthesized in this report establishes serine as a central and indispensable regulator of cellular metabolism, with a multifaceted role that bridges energy production, macromolecular synthesis, and sophisticated cell signaling. Its re-evaluation as a "conditionally essential" amino acid is well-supported by the severe pathologies arising from its deficient synthesis and the heightened metabolic reliance observed in rapidly proliferating cells.

The most striking feature of serine's biology is the functional divergence of its stereoisomers. L-serine serves as the metabolic workhorse, providing the structural foundation for proteins and lipids and acting as the primary source of one-carbon units that fuel the synthesis of nucleotides and regulate the cell's methylation potential. In contrast, D-serine functions as a specialized neuromodulator, a critical co-agonist of the NMDA receptor essential for synaptic plasticity and cognitive function. This L-to-D conversion, mediated by serine racemase, represents a key control point in the brain, capable of translating a metabolic precursor into a potent modulator of excitatory neurotransmission.

This biochemical duality is mirrored in its therapeutic landscape, which is characterized by a fascinating paradox. For a class of genetic and neurological disorders defined by metabolic deficiency or the production of toxic byproducts (e.g., serine biosynthesis defects, HSAN1), high-dose L-serine supplementation has proven to be a viable and effective therapeutic strategy. Conversely, for cancer, a condition often characterized by metabolic hyperactivity and addiction to the serine synthesis pathway, the therapeutic approach is one of depletion and inhibition. This dichotomy underscores that serine is not a simple nutrient but a powerful metabolic modulator whose therapeutic application must be precisely tailored to the underlying pathophysiology of the disease.

Based on this comprehensive analysis, several key future directions for research and development emerge:

1. Advancement of Clinical Trials for Neurodegeneration: The promising but preliminary findings from early-phase clinical trials of L-serine in ALS and Alzheimer's disease warrant validation in larger, placebo-controlled Phase II/III studies. These trials should aim to confirm efficacy, optimize dosing, and identify patient subpopulations most likely to benefit.
2. Overcoming Pharmacokinetic Barriers: A major challenge for the use of L-serine in CNS disorders is its rapid systemic clearance and inefficient transport across the blood-brain barrier. Future research should focus on strategies to overcome these limitations. This could include the development of novel formulations for sustained release, pro-drugs with enhanced CNS penetration, or adjunctive therapies that modulate serine transporters or inhibit its systemic degradation pathways.
3. Targeted Cancer Therapies: The development of therapies that target serine metabolism in cancer remains a highly promising field. Future efforts should focus on creating more potent and selective inhibitors of key enzymes like PHGDH. Critically, success in this area will likely depend on robust patient stratification strategies, using metabolic profiling and genomic biomarkers to identify tumors that are most dependent on the serine synthesis pathway and are therefore most vulnerable to its inhibition.
4. Elucidation of D-Serine's Role: Further investigation into D-serine as both a therapeutic agent and a biomarker is crucial. Validating its potential as a diagnostic or prognostic marker for Alzheimer's disease and other neurological disorders could provide valuable clinical tools. Additionally, refining the therapeutic use of D-serine or DAAO inhibitors for conditions like schizophrenia requires a deeper understanding of its complex role in NMDA receptor signaling and its long-term safety profile.

In conclusion, serine stands as a molecule of immense scientific and clinical interest. Its journey from being considered a simple, non-essential nutrient to a central metabolic regulator and a target for diverse therapeutic interventions highlights the ever-evolving understanding of human biochemistry. Continued research into its complex biology and pharmacology holds significant promise for addressing some of the most challenging diseases in modern medicine.

Works cited

1. Serine - Wikipedia, accessed September 3, 2025, https://en.wikipedia.org/wiki/Serine
2. Serine - HyperPhysics, accessed September 3, 2025, http://hyperphysics.phy-astr.gsu.edu/hbase/Organic/serine.html
3. Serine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 3, 2025, https://go.drugbank.com/drugs/DB00133
4. L-Serine | C3H7NO3 | CID 5951 - PubChem, accessed September 3, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/L-Serine
5. L-Serine | CAS 56-45-1 - Tocris Bioscience, accessed September 3, 2025, https://www.tocris.com/products/l-serine_0227
6. L-Serine - Cayman Chemical, accessed September 3, 2025, https://www.caymanchem.com/product/33561/l-serine
7. L-Serine 56-45-1 | TCI AMERICA - Tokyo Chemical Industry, accessed September 3, 2025, https://www.tcichemicals.com/US/en/p/S0035
8. Serine - (Anatomy and Physiology I) - Vocab, Definition, Explanations | Fiveable, accessed September 3, 2025, https://library.fiveable.me/key-terms/anatomy-physiology/serine
9. Serine: Definition, Structure, Benefits, Types and Uses - BOC Sciences, accessed September 3, 2025, https://aapep.bocsci.com/resources/serine-definition-structure-benefits-types-and-uses.html
10. Serine Amino Acids: Properties, Function, Benefits, and Sources - Creative Peptides, accessed September 3, 2025, https://www.creative-peptides.com/resources/serine-amino-acids-properties-function-benefits-and-sources.html
11. Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid - PMC - PubMed Central, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9105362/
12. Structure of Serine - BYJU'S, accessed September 3, 2025, https://byjus.com/chemistry/serine/
13. SAFETY DATA SHEET - Fisher Scientific, accessed September 3, 2025, https://www.fishersci.com/store/msds?partNumber=BP393100&productDescription=L-SERINE+100G&vendorId=VN00033897&countryCode=US&language=en
14. L-Serine (CAS 56-45-1) - R&D Systems, accessed September 3, 2025, https://www.rndsystems.com/products/l-serine_0227
15. MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated) (DB00133) | DrugBank Online, accessed September 3, 2025, https://go.drugbank.com/spectra/ms_ms/295
16. GC-MS Spectrum - EI-B (DB00133) | DrugBank Online, accessed September 3, 2025, https://go.drugbank.com/spectra/c_ms/30057
17. 1H NMR Spectrum (DB00133) | DrugBank Online, accessed September 3, 2025, https://go.drugbank.com/spectra/nmr_one_d/1157
18. Serine Synthesis | Biochemistry - YouTube, accessed September 3, 2025, https://www.youtube.com/watch?v=ZPzp72SbfU4
19. Resurgence of Serine: An Often Neglected but Indispensable Amino Acid - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3370164/
20. Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid, accessed September 3, 2025, https://www.mdpi.com/2072-6643/14/9/1987
21. Informing Pharmacokinetic Models With Physiological Data: Oral Population Modeling of L-Serine in Humans - Frontiers, accessed September 3, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.643179/pdf
22. Serine and glycine metabolism in cancer - PMC - PubMed Central, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3989988/
23. Serine Metabolism in Health and Disease and as a Conditionally, accessed September 3, 2025, https://pubmed.ncbi.nlm.nih.gov/35565953/
24. L-Serine, non-essential amino acid (CAS 56-45-1) - Abcam, accessed September 3, 2025, https://www.abcam.com/en-us/products/biochemicals/l-serine-non-essential-amino-acid-ab146264
25. Sources and Sinks of Serine in Nutrition, Health, and Disease - PMC - PubMed Central, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10783795/
26. pmc.ncbi.nlm.nih.gov, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9105362/#:~:text=L%2Dserine%20is%20a%20substrate,concentrated%20in%20all%20cell%20membranes.
27. (PDF) Serine Metabolism in Health and Disease and as a Conditionally Essential Amino Acid - ResearchGate, accessed September 3, 2025, https://www.researchgate.net/publication/360495677_Serine_Metabolism_in_Health_and_Disease_and_as_a_Conditionally_Essential_Amino_Acid
28. Pathways of serine synthesis and metabolism. 1, serine hydroxymethyltransferase - ResearchGate, accessed September 3, 2025, https://www.researchgate.net/figure/Pathways-of-serine-synthesis-and-metabolism-1-serine-hydroxymethyltransferase-2_fig4_360495677
29. Serine metabolism - Reactome, accessed September 3, 2025, https://reactome.org/content/detail/R-HSA-977347
30. L-Serine - Nutricia UK, accessed September 3, 2025, https://www.nutricia.co.uk/patients-carers/pim-products/l-serine.html
31. Serine and Metabolism Regulation: A Novel Mechanism in Antitumor Immunity and Senescence - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7673844/
32. The importance of serine metabolism in cancer | Journal of Cell Biology, accessed September 3, 2025, https://rupress.org/jcb/article-abstract/214/3/249/38693
33. Serine racemase: A glial enzyme synthesizing d-serine to regulate glutamate-N-methyl-d-aspartate neurotransmission | PNAS, accessed September 3, 2025, https://www.pnas.org/doi/full/10.1073/pnas.96.23.13409
34. D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression? - Frontiers, accessed September 3, 2025, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2019.00025/full
35. www.pnas.org, accessed September 3, 2025, https://www.pnas.org/doi/10.1073/pnas.0601910103#:~:text=Serine%20proteases%20catalyze%20peptide%20bond,of%20the%20C%2Dterminal%20fragment.
36. Serine protease - Wikipedia, accessed September 3, 2025, https://en.wikipedia.org/wiki/Serine_protease
37. Population pharmacokinetic and pharmacodynamic model guided weight-tiered dose of AST-001 in pediatric patients with autism spectrum disorder - Frontiers, accessed September 3, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1452526/full
38. Pharmacokinetics of oral l-serine supplementation in a single patient ..., accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7256326/
39. (PDF) Pharmacokinetics of oral L-serine supplementation in a single patient - ResearchGate, accessed September 3, 2025, https://www.researchgate.net/publication/341577197_Pharmacokinetics_of_oral_L-serine_supplementation_in_a_single_patient
40. Informing Pharmacokinetic Models with Physiological Data: Oral Population Modeling of L-Serine in Humans | medRxiv, accessed September 3, 2025, https://www.medrxiv.org/content/10.1101/2019.12.07.19011429v1.full-text
41. Pharmacokinetics of oral l-serine supplementation in a single patient - PubMed, accessed September 3, 2025, https://pubmed.ncbi.nlm.nih.gov/32489882/
42. L-serine: Neurological Implications and Therapeutic Potential - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10452085/
43. Informing Pharmacokinetic Models With Physiological ... - Frontiers, accessed September 3, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.643179/full
44. D-Serine: A Cross Species Review of Safety - Frontiers, accessed September 3, 2025, https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.726365/full
45. D-Serine: A Cross Species Review of Safety - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8384137/
46. Serine Completed Phase 3 Trials for Parenteral Nutrition for Patients With Proven Insufficient Enteral Resorption Treatment - DrugBank, accessed September 3, 2025, https://go.drugbank.com/drugs/DB00133/clinical_trials?conditions=DBCOND0049925&phase=3&purpose=treatment&status=completed
47. Low Birth Weight Completed Phase 3 Trials for Serine (DB00133) | DrugBank Online, accessed September 3, 2025, https://go.drugbank.com/indications/DBCOND0031133/clinical_trials/DB00133?phase=3&status=completed
48. Serine - Content - Health Encyclopedia - University of Rochester Medical Center, accessed September 3, 2025, https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=19&contentid=Serine
49. Serine – MONTERANC, accessed September 3, 2025, https://monteranc.com/blogs/ingredient/serine
50. Serine (Explained + Products) - INCIDecoder, accessed September 3, 2025, https://incidecoder.com/ingredients/serine
51. Serine in Skin Care: What It Is and Is It Safe? | Paula's Choice, accessed September 3, 2025, https://www.paulaschoice.com/ingredient-dictionary/ingredient-serine.html
52. The Benefits of Serine for Hair and Scalp | Divi, accessed September 3, 2025, https://www.diviofficial.com/blogs/ingredients/serine-benefits-for-hair-and-scalp
53. Serine in skincare, What is? - Lesielle, accessed September 3, 2025, https://www.lesielle.com/int/en/serine-in-skincare-what-is-inci-1502
54. An epidermal serine sensing system for skin healthcare - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11920223/
55. Trials of L-serine in ALS (P3.128) | Neurology, accessed September 3, 2025, https://www.neurology.org/doi/10.1212/WNL.88.16_supplement.P3.128
56. L-Serine Safety for ALS · Info for Participants - Clinical Trials, accessed September 3, 2025, https://www.withpower.com/trial/phase-2-motor-neuron-disease-2013-57726
57. Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study | NEALS, accessed September 3, 2025, https://neals.org/als-trials/nct03580616
58. L-Serine Health Benefits: From Brain Health to Better Sleep ... - iHerb, accessed September 3, 2025, https://www.iherb.com/blog/l-serine-health-benefits-brain-sleep/1687
59. L-serine — Brain Chemistry Labs The Institute for EthnoMedicine, accessed September 3, 2025, https://brainchemistrylabs.org/lserine
60. L-Serine - Alzheimer's Drug Discovery Foundation, accessed September 3, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/L-serine-Cognitive-Vitality-For-Researchers.pdf
61. L-Serine Trial Update - CureGRIN Foundation, accessed September 3, 2025, https://curegrin.org/l-serine-trial-update/
62. Randomized trial of l-serine in patients with hereditary sensory and ..., accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6345118/
63. L‐serine: a neglected amino acid with a potential therapeutic role in diabetes - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6851881/
64. The role of serine metabolism in lung cancer: From oncogenesis to tumor treatment, accessed September 3, 2025, https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.1084609/full
65. The importance of serine metabolism in cancer - PMC - PubMed Central, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4970329/
66. The role and research progress of serine metabolism in tumor cells - PMC - PubMed Central, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12011608/
67. The role and research progress of serine metabolism in tumor cells - Frontiers, accessed September 3, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1509662/pdf
68. Taking advantage of cancers' abnormal metabolism could lead to a new way to 'starve' tumours, accessed September 3, 2025, https://news.cancerresearchuk.org/2017/04/19/taking-advantage-of-cancers-abnormal-metabolism-could-lead-to-a-new-way-to-starve-tumours/
69. Targeting Serine in Cancer: Is Two Better Than One? - PMC, accessed September 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9097339/
70. L-Serine & Your Brain | Cognitive Vitality | Alzheimer's Drug ..., accessed September 3, 2025, https://www.alzdiscovery.org/cognitive-vitality/ratings/l-serine
71. Transcriptome Analysis Reveals Potential Mechanisms of L-Serine ..., accessed September 3, 2025, https://www.mdpi.com/2304-8158/11/14/2092
72. Advances in Metabolic Engineering of Microbial Cell Factories for ..., accessed September 3, 2025, https://pubs.acs.org/doi/10.1021/acs.jafc.5c07884
73. Serine synthesis - US2530065A - Google Patents, accessed September 3, 2025, https://patents.google.com/patent/US2530065A/en
74. L-serine production by a methylotroph and its related enzymes - PubMed, accessed September 3, 2025, https://pubmed.ncbi.nlm.nih.gov/7763921/
75. Metabolic Engineering of Corynebacterium glutamicum for l-Serine ..., accessed September 3, 2025, https://journals.asm.org/doi/10.1128/aem.71.11.7139-7144.2005
76. Bioprocess Engineering, Transcriptome, and Intermediate Metabolite Analysis of L-Serine High-Yielding Escherichia coli W3110 - MDPI, accessed September 3, 2025, https://www.mdpi.com/2076-2607/10/10/1927
77. High-yield production of l-serine from glycerol by engineered Escherichia coli | Journal of Industrial Microbiology and Biotechnology | Oxford Academic, accessed September 3, 2025, https://academic.oup.com/jimb/article/46/2/221/5997147
78. Microbial Production of l-Serine from Renewable Feedstocks - PubMed, accessed September 3, 2025, https://pubmed.ncbi.nlm.nih.gov/29500004/
79. Serine: Benefits, Dosage, Contraindications - Darwin Nutrition, accessed September 3, 2025, https://www.darwin-nutrition.fr/en/active/serine/
80. D-Serine & Your Brain | Cognitive Vitality | Alzheimer's Drug Discovery Foundation, accessed September 3, 2025, https://www.alzdiscovery.org/cognitive-vitality/ratings/d-serine
81. Serine - Health Library, accessed September 3, 2025, https://myhealth.umassmemorial.org/library/Wellness/Safety/19,Serine
82. Serine - Health Library, accessed September 3, 2025, https://myhealth.umassmemorial.org/Conditions/Heart/Tools/19,Serine
83. Serine | OSF HealthCare - Health Library, accessed September 3, 2025, https://healthlibrary.osfhealthcare.org/Library/DiseasesConditions/Adult/PhysicalMed/19,Serine
84. d‐Serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis | The EMBO Journal, accessed September 3, 2025, https://www.embopress.org/doi/abs/10.1038/sj.emboj.7601840
85. L-serine: Neurological Implications and Therapeutic Potential - MDPI, accessed September 3, 2025, https://www.mdpi.com/2227-9059/11/8/2117
86. d‐Serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis | The EMBO Journal, accessed September 3, 2025, https://www.embopress.org/doi/10.1038/sj.emboj.7601840
87. The Mental Health Benefits of Phosphatidylserine - Verywell Mind, accessed September 3, 2025, https://www.verywellmind.com/the-benefits-of-phosphatidylserine-89496
88. PHOSPHATIDYLSERINE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed September 3, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-992/phosphatidylserine
89. Phosphatidylserine: Uses and Risks - WebMD, accessed September 3, 2025, https://www.webmd.com/vitamins-and-supplements/phosphatidylserine-uses-and-risks
90. Phosphatidylserine: What It Is, Benefits, Side Effects & Uses - Cleveland Clinic, accessed September 3, 2025, https://my.clevelandclinic.org/health/drugs/25129-phosphatidylserine
91. Showing Compound L-Serine (FDB012739) - FooDB, accessed September 3, 2025, https://foodb.ca/compounds/FDB012739